CAMBRIDGE, Mass., April 12 /PRNewswire-FirstCall/ -- Advanced Magnetics, Inc. today announced that it will report second fiscal quarter 2007 financial results after the U.S. financial markets close on Wednesday, April 25, 2007. The announcement will be followed by a conference call at 4:30 p.m. ET during which management will discuss the company’s financial results, quarterly highlights and clinical development programs.
An audio webcast of the earnings call will be available through the Investors section of the company’s website at www.advancedmagnetics.com. The webcast will also be available as a replay, starting approximately one hour after the call is completed, through May 25, 2007.
To access the conference call via telephone, please dial (800) 819-9193 from the United States or (913) 981-4911 for international access. A telephone replay will be available from approximately 7:30 p.m. ET on April 11 through April 12. To access a replay of the conference call, dial (888) 203-1112 from the United States or (719) 457-0820 for international access. The passcode for both replay numbers is of 5320343.
About Advanced Magnetics
Advanced Magnetics, Inc. is a developer of superparamagnetic iron oxide nanoparticles used in pharmaceutical products. As a leader in our field, we are dedicated to the development and commercialization of our proprietary nanoparticle technology for use in therapeutic iron compounds to treat anemia, as well as novel imaging agents to aid in the diagnosis of cardiovascular disease and cancer.
Ferumoxytol, the company’s key product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease. The company plans to file a New Drug Application for marketing approval of ferumoxytol with the U.S. Food and Drug Administration during the fourth calendar quarter of 2007.
Combidex(R), the company’s second product under development, is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with magnetic resonance imaging, or MRI, to aid in the differentiation of cancerous from normal lymph nodes. In March 2005, the company received an approvable letter from the FDA with respect to Combidex, subject to certain conditions.
Contacts: Investors: Kristen Galfetti kgalfetti@advancedmagnetics.com (617) 498-3362
Advanced Magnetics, Inc.
CONTACT: Investors, Kristen Galfetti of Advanced Magnetics, Inc.,+1-617-498-3362, kgalfetti@advancedmagnetics.com
Web site: http://www.advancedmagnetics.com/
